Shilpa Medicare receives USFDA approval for Bortezomib injection
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Subscribe To Our Newsletter & Stay Updated